Welcome to our dedicated page for Orgenesis news (Ticker: ORGS), a resource for investors and traders seeking the latest updates and insights on Orgenesis stock.
Orgenesis Inc. reports developments in cell and gene therapies, decentralized cell processing, and regenerative medicine. Company news has centered on its CGT platform, GMP-validated production capabilities for CAR-T, tumor-infiltrating lymphocytes, lentivirus vectors, oncolytic virus cell carriers, and therapeutic exosomes, as well as ORG-101, a CD19 CAR-T therapy studied in acute lymphoblastic leukemia.
Recurring updates also cover portfolio expansion through regenerative medicine assets for spinal cord injury, partnerships with hospitals, research institutions, and healthcare groups, and financing arrangements used to support platform rollout. Corporate news includes trading-market changes, reverse stock split actions, listing-compliance matters, and other capital-structure developments affecting ORGS common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Orgenesis (NASDAQ: ORGS), a global biotech company focused on cell and gene therapies, announced CEO Vered Caplan's participation in a keynote series at the INTERPHEX conference in New York from April 25-27, 2023. Caplan will discuss innovations from the Company’s POCare Services subsidiary, including Orgenesis Mobile Processing Units and Labs (OMPULs), which aim to provide cost-effective, decentralized therapies at the point of care. This event showcases advancements in the pharmaceutical lifecycle and highlights regulatory support for continuous manufacturing in the biopharma industry. Orgenesis seeks to enhance the accessibility and affordability of cell and gene therapies globally through its innovative POCare Platform.
Orgenesis Inc. (NASDAQ: ORGS) announced a substantial revenue growth of 98% in Q4 2022, amounting to $13.6 million compared to $6.9 million in Q4 2021. The company's operating loss significantly decreased by 91%, demonstrating the effectiveness of its cost-efficient business model. Key advancements included signing a non-binding MOU with UC Davis for the deployment of Orgenesis Mobile Processing Units and Labs (OMPULs) and facilitating positive cash flow through its subsidiary Koligo Therapeutics. The company continues to expand its POCare therapeutic pipeline and leverage partnerships for growth. A conference call to discuss these developments is scheduled for today at 11:00 AM ET.
Orgenesis Inc. (NASDAQ: ORGS), a global biotech firm, will host a conference call on March 21, 2023, at 11:00 AM ET to discuss its corporate progress and developments. Interested participants can dial in or join via webcast on the company’s website. A replay will be available for one year post-event. Orgenesis focuses on optimizing cell and gene therapies, utilizing its POCare Platform to provide accessible treatments globally. The company emphasizes innovation in treatment development and delivery, targeting large patient populations through a collaborative network.
Orgenesis (NASDAQ: ORGS) has signed a non-binding memorandum of understanding (MOU) with UC Davis to deploy its proprietary Orgenesis Mobile Processing Units and Labs™ (OMPULs™) across California. The partnership aims to create a decentralized model for the development and manufacture of cell and gene therapies at point-of-care facilities in the state. The first stage focuses on establishing an OMPUL at UC Davis within 12 months of a definitive agreement. This collaboration is expected to lower costs and improve accessibility to these therapies for patients.
Orgenesis, Inc. (Nasdaq: ORGS) has completed a Registered Direct Offering, raising approximately $3.7 million by issuing 1,947,368 common shares and warrants at a price of $1.90 per share. Each warrant allows the purchase of an additional common share at the same exercise price and expires in five years. The proceeds will be used for general corporate purposes, including working capital and administrative expenses. Joseph Gunnar & Co., LLC served as the placement agent. This offering is registered under an effective shelf registration statement with the SEC.